Cargando…
Intranasal administration of acetylcholinesterase inhibitors
This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeutically viable formulation. In vivo testing confirmed achievement of therapeutically relevant...
Autores principales: | Costantino, Henry R, Leonard, Alexis Kays, Brandt, Gordon, Johnson, Paul H, Quay, Steven C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604884/ https://www.ncbi.nlm.nih.gov/pubmed/19091003 http://dx.doi.org/10.1186/1471-2202-9-S3-S6 |
Ejemplares similares
-
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
por: Walczak-Nowicka, Łucja Justyna, et al.
Publicado: (2021) -
Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors
por: Ferris, Steven H, et al.
Publicado: (2013) -
Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity
por: Pohanka, Miroslav
Publicado: (2014) -
Intranasal Administration for Pain: Oxytocin and Other Polypeptides
por: Bharadwaj, Vimala N., et al.
Publicado: (2021) -
Design and Efficacy of Nanogels Formulations for Intranasal Administration
por: Aderibigbe, Blessing A., et al.
Publicado: (2018)